Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro

Abstract

The strongest cytotoxic effect of RIT in the presence of AS suggests that this drug activity towards CLL cells is enhanced by known cytotoxic mechanisms, caspase-dependent apoptotic pathway and possible influence of other extracellular factors present in the patients' sera.

The Influence of Maltotriose-Modified Poly(propylene imine) Dendrimers on the Chronic Lymphocytic Leukemia Cells in Vitro: Dense Shell G4 PPI

“…If the autologous serum had been used, better results would have been obtained with a lower Rit concentration. 55 The initial cause of CLL remains an open question, but it is currently well-accepted that the accumulation of leukemic cells is partially explained by a defect in apoptosis. However, recent studies suggest that CLL is not solely an accumulation disease but also a proliferative one.…”

“…This is a monoclonal antibody, and its effectiveness in natural environment depends on known cytotoxic mechanism, caspase-dependent apoptotic pathway, and possible influence of other extracellular factors present in the patient’s serum. If the autologous serum had been used, better results would have been obtained with a lower Rit concentration …”

Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles

“…Commercially available Fludarabine (FA, Genzyme) was used in the study. Chosen concentration of 1.6 μM is the IC 50 of FA in 24-h culture and was calculated on the basis of previous studies (Ziółkowska et al, 2012;Zaborowska et al, 2009). It is close to the concentration of the drug given to patients during the standard treatment protocol (Korycka and Robak, 2003).…”

Механизмы Действия Ритуксимаба

“…Öèòîòîêñè-÷åñêîå äåéñòâèå ðèòóêñèìàáà íå çàâèñåëî îò åãî êîí-öåíòðàöèè, íî çàâèñåëî îò òèïà ñûâîðîòêè. Òàêèì îá-ðàçîì, óâåëè÷åíèå öèòîòîêñè÷íîñòè ðèòóêñèìàáà â ïðèñóòñòâèè àóòîëîãè÷åñêîé ñûâîðîòêè óêàçûâàåò íà òî, ÷òî ðèòóêñèìàá äåéñòâóåò íà êëåòêè ÕËË ïîñðåä-ñòâîì ðåàëèçàöèè ÀÇÊÖ, à òàêaeå êàñïàç-çàâèñèìîãî àïîïòîçíîãî ïóòè è, âîçìîaeíî, ïîñðåäñòâîì âëèÿíèÿ íà äðóãèå ýêñòðàêëåòî÷íûå ôàêòîðû, ïðèñóòñòâóþùèå â ñûâîðîòêå êðîâè ïàöèåíòîâ [32].…”